• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.67% Nasdaq Up1.47%

    BioTime, Inc. (BTX)

    -NYSE MKT
    4.71 Up 0.15(3.29%) May 27, 4:02PM EDT
    |After Hours : 4.71 0.00 (0.00%) May 27, 4:22PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    BioTime, Inc.
    1301 Harbor Bay Parkway
    Alameda, CA 94502
    United States - Map
    Phone: 510-521-3390
    Fax: 510-521-3389
    Website: http://www.biotimeinc.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:117

    Business Summary 

    BioTime, Inc., a biotechnology company, engages in the research and product development in the field of regenerative medicine. The company focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including PureStem human embryonic progenitor cell lines; associated ESpan culture media; human embryonic stem cell lines; HyStem hydrogel products; and Hextend, a blood plasma volume expander for hypovolemia in surgery, emergency trauma, and other applications. The company’s clinical programs include OpRegen and OpRegen-Plus, which are in Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1 that is in Phase I/IIa trial for spinal cord injuries; Renevia, which is in pivotal trial for HIV-related lipoatrophy; and AST-VAC2 that is in pre-clinical stage for non-small cell lung cancer. It is also developing Premvia, a hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and PanC-Dx, a diagnostic product used to detect breast, bladder, and lung cancers, as well as mobile health software products. In addition, the company markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; VarElect, an application for prioritizing gene variants; and MalaCards, a database of human diseases, as well as analysis tools. Further, it develops cell based therapeutic products for diseases, such as neurological, cancer, age related macular degeneration, orthopedic, and age-related cardiovascular diseases. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BioTime, Inc.

    Corporate Governance 
    BioTime, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Michael D. West Ph.D., 62
    Chief Exec. Officer, Pres and Director
    922.00K0.00
    Mr. Robert W. Peabody CPA, 61
    Chief Financial Officer, Principal Accounting Officer and Sr. VP
    550.00K0.00
    Mr. Aditya Mohanty ,
    Chief Operating Officer
    5.00K0.00
    Dr. Lesley A. Stolz Ph.D., 51
    Exec. VP of Corp. Devel.
    76.00K0.00
    Ms. Judith Segall , 62
    VP of Admin., Sec. and Director
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders